| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_TTC3_0024500 | Exon-Exon | chr21:38538166-38564506 | chr21:37165864-37192205 | 1560 nt | 0.4096 |
| hsa_chr21_0074700 | Intergenic-Intergenic | chr21:38538232-38544988 | chr21:37165930-37172686 | 92 nt | 0.3696 |
| hsa_TTC3_0024600 | Exon-Exon | chr21:38538268-38538410 | chr21:37165966-37166108 | 143 nt | 0.4685 |
| hsa_TTC3_0024700 | Exon-Exon | chr21:38538310-38545018 | chr21:37166008-37172716 | 796 nt | 0.4384 |
| hsa_TTC3_0024800 | Exon-Exon | chr21:38538334-38545018 | chr21:37166032-37172716 | 772 nt | 0.4365 |
| hsa_TTC3_0024900 | Exon-Exon | chr21:38538334-38545046 | chr21:37166032-37172744 | 800 nt | 0.4338 |
| hsa_chr21_0074800 | Intergenic-Intergenic | chr21:38538358-38544980 | chr21:37166056-37172678 | 710 nt | 0.4338 |
| hsa_TTC3_0025000 | Exon-Exon | chr21:38538361-38544929 | chr21:37166059-37172627 | 656 nt | 0.4436 |
| hsa_TTC3_0025100 | Exon-Exon | chr21:38538384-38544929 | chr21:37166082-37172627 | 633 nt | 0.4439 |
| hsa_TTC3_0025200 | Exon-Exon | chr21:38538491-38539883 | chr21:37166189-37167581 | 454 nt | 0.4427 |
A study in humans demonstrated that the circTTC3 shows a significant decrease in the peripheral blood of Alzheimer's disease patients, suggesting its potential to distinguish this condition from other dementias [Misir et al. DOI:10.1038/s41418-022-00948-7]. In mice and rats, circTTC3 was markedly upregulated in ischemic myocardium post-myocardial infarction and counteracted hypoxia-induced ATP depletion and apoptotic death in cardiomyocytes via the miR-15b/Arl2 axis [Tian et al. DOI:10.3390/molecules26041155]. It also alleviated hypoxic injury in HaCaT cells via miR-449a/NF-κB and PI3K/AKT pathways [Huang et al. DOI:10.3390/cells11091381].